Novo Nordisk's Blood Disorder Breakthrough Offers a Lifeline Amid GLP-1 Gloom

Novo Nordisk’s share price, languishing more than 50% below its June 2025 peak, has found a potential catalyst far from its core diabetes and obesity business. The Danish pharmaceutical giant has reported positive late-stage trial results for etavopivat, an oral treatment for sickle cell disease, providing a strategic bright spot as its foundational GLP-1 franchise faces mounting pressure.

The Phase 3 HIBISCUS trial, involving 385 patients aged 12 and older, successfully met both co-primary endpoints. Data showed the therapy reduced painful vaso-occlusive crises by 27% compared to a placebo. A more pronounced effect was seen on hemoglobin levels: nearly 49% of patients receiving etavopivat achieved an increase of at least 1 g/dL after 24 weeks, versus just 7.2% in the control group. The time to the first vaso-occlusive event also extended significantly, from just under 21 weeks to over 38 weeks. The company reported a clean safety profile with no unexpected adverse events.

This clinical success carries added weight given recent competitive turmoil. Rival Pfizer’s ambitious push into the sickle cell disease market, anchored by a multi-billion dollar acquisition, ended in failure. The U.S. firm was forced to withdraw its already-approved drug, Oxbryta, globally in September 2024 after data revealed an imbalance in fatal events. Novo Nordisk now stands to fill that void with etavopivat, a drug it acquired through its $1.1 billion purchase of Forma Therapeutics in 2022.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

For Novo Nordisk, the timing is critical. Management forecasts a currency-adjusted sales decline of 5% to 13% for 2026 in its core business, reflecting intensifying competition and pricing pressure in the GLP-1 market. The sickle cell disease opportunity, targeting a global patient population of approximately eight million, represents a strategic diversification into a chronically underserved market with significant pricing potential. The drug already holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, along with Orphan status in Europe.

Concurrently, the company is supporting its equity through a substantial share buyback program. As part of a 15-billion Danish krone initiative, Novo Nordisk has repurchased around 12.3 million B-shares since February, worth approximately 3.15 billion DKK. The company now holds 0.7% of its own share capital as treasury stock.

Trading at 34.56 euros, the stock remains deeply oversold, with its Relative Strength Index at 24.6. The planned next step is for Novo Nordisk to submit its first regulatory applications for etavopivat in the second half of 2026, following a detailed data presentation at a scientific conference. If approved, the therapy could establish the rare disease segment as a tangible second growth pillar for the company from 2027 onward.

Ad

Novo Nordisk Stock: New Analysis - 21 April

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69224281 |